Market Place
Sourcing Support
Kyowa Announces Acceptance of Abstract for Presentation at the Annual Meeting
02 Apr 2024 //
PR NEWSWIRE
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Evaluating Tivozanib
06 Feb 2024 //
PR NEWSWIRE
AVEO Announces Completion of Enrollment in Pivotal Ph3 TiNivo-2 Study of FOTIVDA
27 Jun 2023 //
PR NEWSWIRE
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Use of FOTIVDA®
12 Oct 2022 //
GLOBENEWSWIRE
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO
06 Jun 2022 //
GLOBENEWSWIRE
AVEO Oncology to Present Positive PFS Data from Phase 3 TIVO-3 Study of FOTIVDA
14 Feb 2022 //
GLOBENEWSWIRE
AVEO Presents 3 Posters for Tivozanib/Immunotherapy Combinations at 2022 ASCO GI
20 Jan 2022 //
GLOBENEWSWIRE
AVEO Reports Q3 2021 Financial Results and Provides Business Update
08 Nov 2021 //
BUSINESSWIRE
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib)
29 Mar 2021 //
PRESS RELEASE
Aveo`s tivozanib, after years of setbacks, wins its FDA nod
11 Mar 2021 //
FIERCEPHARMA
Aveo gets FDA nod for Fotivda in third-line kidney cancer
11 Mar 2021 //
BUSINESSWIRE
AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib)
10 Mar 2021 //
BUSINESSWIRE
FDA approves AVEO’s kidney cancer treatment
10 Mar 2021 //
PHARMAFILE
AVEO Oncology Announces Presentation of Key Subgroup and Quality
11 Feb 2021 //
BUSINESSWIRE
AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life
11 Feb 2021 //
BUSINESSWIRE
AVEO Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib
15 Jan 2021 //
BUSINESSWIRE
AVEO Oncology Announces Results from Ph 1b of DEDUCTIVE Study of Tivozanib
15 Jan 2021 //
PRNEWSWIRE
AVEO Oncology Announces Data from Study of Tivozanib in Renal Cell Carcinoma
15 Sep 2020 //
BUSINESSNEWS WIRE
AVEO Announces Proposed Public Offering of Common Stock
15 Jun 2020 //
BUSINESSWIRE
AVEO Oncology Announces FDA Acceptance for Filing of a NDA for Tivozanib
01 Jun 2020 //
BUSINESSWIRE
AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib)
29 May 2020 //
BUSINESSWIRE
AVEO Announces Change to Virtual Annual Meeting of Stockholders
27 May 2020 //
BUSINESSWIRE
AVEO Oncology to Present Final Survival Analysis Ph3 TIVO-3 Trial of Tivozanib
29 Apr 2020 //
BUSINESSWIRE
AVEO Oncology Announces Submission of NDA to U.S. FDA for Tivozanib
31 Mar 2020 //
BUSINESSWIRE
AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib
13 Feb 2020 //
BUSINESSWIRE
Could the anti-cancer gene p53 be a target in treating kidney cancer?
21 Dec 2019 //
FIERCE BIOTECH
AVEO Announces Presentation of OS and Subgroup Data from Phase 3 TIVO-3 Trial
18 Nov 2019 //
BIOSPACE
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma
05 Nov 2019 //
BUSINESSWIRE
FDA tells Aveo no, again, for tivozanib
05 Nov 2019 //
BIOSPACE
With Stronger OS Data, AVEO Plans to Seek Approval of RCC Drug Tivozanib
11 Sep 2019 //
BIOSPACE
Kyowa Kirin buys back Tivozanib rights from AVEO oncology
01 Aug 2019 //
BIOSPECTRUMASIA
FDA stiff-arms Aveo on tivo, again; Sunovion Parkinson’s drug rejected
01 Feb 2019 //
ENDPTS
AstraZeneca, AVEO Oncology form lung cancer collaboration
12 Dec 2018 //
PHARMA TIMES
Former Aveo CFO found guilty of misleading investors
22 Nov 2018 //
FIERCE PHARMA
AVEO Announces Proposed Offering of Common Stock
17 Aug 2018 //
BUSINESSWIRE
AVEO Announces Pricing of $5.7 Million Public Offering of Common Stock
17 Aug 2018 //
BUSINESSWIRE
EUSA Pharma Announces Sale of Critical Care Business to SERB Pharmaceuticals
11 Jul 2018 //
PR NEWSWIRE
Three cancer treatments approved for use on NHS Scotland
10 Jul 2018 //
PHARMA TIMES
